Therapeutic Antibodies against ROR-1 Protein and Methods for Use of Same
AssigneeThe Regents of the University of California
InventorsThomas J. Kipps, George F. Widhopf, II, Bing Cui
Life of this patent
Estimating the term…
Abstract
Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
Claims27
An isolated antibody that specifically binds ROR1 protein and is comprised of a heavy chain region coded by polynucleotides having at least 90% sequence identity with any of the sequences of SEQ ID NOs:
- 1, 5, 9, 13 or 17, and a corresponding light chain region having at least 90% sequence identity with any of the sequences of SEQ ID NOs:
- 3, 7, 11, 15 or 19.
An isolated antibody that specifically binds ROR1 protein and is comprised of a heavy chain region consisting of polypeptides having at least 90% sequence identity with any of the sequences of SEQ ID NOs:
- 2, 6, 10, 14 or 18, and a corresponding light chain region having at least 90% sequence identity with any of the sequences of SEQ ID NOs:
- 4, 8, 12, 16 or 20.
An isolated polynucleotide which encodes an antibody that specifically binds ROR1 protein and is comprised of a heavy chain region coded by polynucleotides having at least 90% sequence identity with any of the sequences selected from the group consisting of SEQ ID NOs:
- 1, 5, 9, 13 or 17, and a corresponding light chain region encoded by polynucleotides having at least 90% sequence identity with any of the sequences selected from the group consisting of SEQ ID NOs:
- 3, 7, 11, 15 or 19.
An isolated polypeptide that specifically binds ROR1 protein and is comprised of a heavy chain region having at least 90% sequence identity with any of the sequences selected from the group consisting of SEQ ID NOs:
- 2, 6, 10, 14 or 18, and a corresponding light chain region having at least 90% sequence identity with any of the sequences selected from the group consisting of SEQ ID NOs:
- 4, 8, 12, 16 or 20.
An isolated antibody which binds the same epitope as antibody 4A5 or D10.
Dependencies are inferred from the claim text.